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Stimulating Factor in the Treatment of
Neurological DiseasesAlthough stem cell therapy was suggested to have a ther-
apeutic effect on different neurological disease models,
finding suitable sources of stem cells is a great challenge.
Recent studies have reported new migrating stem cells in
the brain of many animal models and humans. Bone
marrow-derived cells were also found to be able to differ-
entiate into neuronal and vascular cells, aiding in the repair
of an injured brain. These interesting findings in regener-
ative medicine for neurological diseases push us to think
whether increasing the endogenous circulating stem cells in
blood can be used to treat neurological diseases in humans.
Using drugs to mobilize endogenous bone marrow-derived
cells or other endogenous stem cells may be a potential
choice in the future to increase the number of circulating
stem cells for therapy. Of those potential drugs,
granulocyte-colony stimulating factor (G-CSF) is the most
commonly mentioned.
The G-CSF is a hematopoietic growth factor, named for
its role in the proliferation and differentiation of cells of
the myeloid lineage.1 Administration of G-CSF can mobilize
hematopoietic stem cells (HSCs) from the bone marrow into
the peripheral blood. The G-CSF has been used extensively
for more than 10 years in the treatment of chemotherapy-
induced neutropenia, as well as for bone marrow recon-
stitution and stem cell mobilization. The peripheral blood-
derived HSCs have been used in place of bone marrow cells
for the regeneration of nonhematopoietic tissues such as
skin, skeletal muscle, and myocardium. The G-CSF was also
shown to display robust in vitro and in vivo neuroprotective
activity by inhibiting apoptosis and inflammation, and was
widely applied in the repair of neurological disease models.
The most common models using G-CSF for therapy are
stroke animal models. Administration of G-CSF in stroke
models could induce neurogenesis in the damaged area
leading to the repair of damaged neurons. Its anti-
inflammatory actions have also been shown to contribute
to the neuroprotective effect. Treatment with G-CSF can1875-9572/$36 Copyright ª 2013, Taiwan Pediatric Association. Publish
http://dx.doi.org/10.1016/j.pedneo.2013.08.004also augment cerebral collateral artery growth and in-
crease cerebrovascular reserve capacity, subsequently
leading to protection from neuronal death. Because of
increasing evidence of the beneficial effects of G-CSF
treatment, many pilot studies have been carried out, the
results of which show G-CSF therapy to be safe and feasible
in adults with strokes.2
Recently, treatment with G-CSF was also found to induce
neurogenesis and repair memory and neurobehavioral loss
in an animal model of Alzheimer disease.3 In addition to
focusing on the application in stroke or other neurological
disease models, some studies have recently focused on the
beneficial effects of G-CSF treatment in neonatal brains
after perinatal hypoxia. As shown in recent studies, with
the application of G-CSF, the neurogenesis in hippocampus,
dentate gyrus, midbrain, and temporal lobe significantly
increased after perinatal hypoxia.4,5 The G-CSF therapy
also markedly improved the decreased performance of
long-term cognitive functions induced by perinatal hypoxia.
This indicated that G-CSF may be a potentially beneficial
therapy through recovery and increase of neurogenesis in
the neonatal brain after perinatal hypoxia insult.
In addition to G-CSF, stem cell factor (SCF), which can
regulate HSCs in the bone marrow, has recently been sug-
gested to have a neuroprotective effect in ischemic stroke
model. Recent studies also found that the combination of
SCF and G-CSF could also augment dendritic branches and
modify neural circuits in mice months after ischemic
stroke.6 It was indicated that combined SCF and G-CSF
treatment may provide better neuroprotective effect, and
that it may have wider application in the future. The
combination of SCF and G-CSF treatment was also shown to
provide a better neuroprotective effect than a single
treatment after perinatal hypoxia insult in rats.7 Although
both G-CSF and combined SCF and G-CSF treatment
decreased brain atrophy after perinatal hypoxic insult, only
combined SCF and G-CSF treatment can have significanted by Elsevier Taiwan LLC. All rights reserved.
354 Editorialimprovement in neurological functions. Therefore, search-
ing for more combined therapy may provide more promising
treatment in the future.Wang-Tso Lee*
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